BNTC vs DBVT vs REGN vs KRYS

For growth investors, Krystal Biotech, Inc.

(KRYS) is the stronger pick with 33. 9% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 2x trailing P/E (15. 5x forward), making it the more compelling value choice. Analysts rate Benitec Biopharma Inc. (BNTC) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 2x versus Krystal Biotech, Inc. at 44. 7x. On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 15. 5x.

Over the past 5 years, Krystal Biotech, Inc.

(KRYS) delivered a total return of +364. 0%, compared to -83. 9% for Benitec Biopharma Inc. (BNTC). Over 10 years, the gap is even starker: KRYS returned +27. 7% versus BNTC's -97. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.

(REGN) is the lower-risk stock at 0. 77β versus Benitec Biopharma Inc. 's 1. 31β — meaning BNTC is approximately 70% more volatile than REGN relative to the S&P 500. On balance sheet safety, Krystal Biotech, Inc. (KRYS) carries a lower debt/equity ratio of 1% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Krystal Biotech, Inc.

(KRYS) is pulling ahead at 33. 9% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Krystal Biotech, Inc. grew EPS 128. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Krystal Biotech, Inc.

(KRYS) is the more profitable company, earning 52. 6% net margin versus -91. 5% for Benitec Biopharma Inc. — meaning it keeps 52. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -99. 9% for BNTC. At the gross margin level — before operating expenses — KRYS leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Regeneron Pharmaceuticals, Inc.

(REGN) trades at 15. 5x forward P/E versus 39. 4x for Krystal Biotech, Inc. — 24. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BNTC: 160. 6% to $32. 00.

In this comparison, REGN (0.

5% yield) pays a dividend. BNTC, DBVT, KRYS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77)). Both have compounded well over 10 years (REGN: +91. 6%, BNTC: -97. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BNTC is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; REGN is a mid-cap deep-value stock; KRYS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.